Yutang Huang

Chongqing, 400016, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Biomimetic fusion nanosystem from ginger exosomes and tumor cell membranes: boosting PLK1-targeted therapy in BRCA-heterogeneous HGSOC.

Biomimetic fusion nanosystem from ginger exosomes and tumor cell membranes: boosting PLK1-targeted therapy in BRCA-heterogeneous HGSOC.

Journal: Journal of nanobiotechnology

Published: February 10, 2026

Targeting intratumoral Streptococcus mitis suppresses the progression of esophageal squamous cell carcinoma.

Targeting intratumoral Streptococcus mitis suppresses the progression of esophageal squamous cell carcinoma.

Journal: Science China. Life sciences

Published: June 26, 2025

Prognostic Value and Immunological Role of CBX7 in Lung Adenocarcinoma.

Prognostic Value and Immunological Role of CBX7 in Lung Adenocarcinoma.

Journal: Current molecular medicine

Published: December 22, 2024

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients.

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients.

Journal: Molecular medicine (Cambridge, Mass.)

Published: June 25, 2024

Cancer-associated fibroblast-derived colony-stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis.

Cancer-associated fibroblast-derived colony-stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis.

Journal: MedComm

Published: November 22, 2023

CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer.

CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer.

Journal: Cancer genetics

Published: April 17, 2023

Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer.

Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer.

Journal: Molecular omics

Published: January 18, 2023

CircSETD3 mediates acquired resistance to gefitinib in non-small lung cancer cells by FXR1/ECT2 pathway.

CircSETD3 mediates acquired resistance to gefitinib in non-small lung cancer cells by FXR1/ECT2 pathway.

Journal: The international journal of biochemistry & cell biology

Published: September 14, 2022

Ct-OATP1B3 promotes high-grade serous ovarian cancer metastasis by regulation of fatty acid beta-oxidation and oxidative phosphorylation.

Ct-OATP1B3 promotes high-grade serous ovarian cancer metastasis by regulation of fatty acid beta-oxidation and oxidative phosphorylation.

Journal: Cell death & disease

Published: September 01, 2021

circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway.

circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway.

Journal: Molecular therapy. Nucleic acids

Published: July 16, 2020

Genome-wide identification and characterization of long non-coding RNAs involved in acquired resistance to gefitinib in non-small-cell lung cancer.

Genome-wide identification and characterization of long non-coding RNAs involved in acquired resistance to gefitinib in non-small-cell lung cancer.

Journal: Computational biology and chemistry

Published: January 23, 2020

Screening Circular RNAs Related to Acquired Gefitinib Resistance in Non-small Cell Lung Cancer Cell Lines.

Screening Circular RNAs Related to Acquired Gefitinib Resistance in Non-small Cell Lung Cancer Cell Lines.

Journal: Journal of Cancer

Published: August 30, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026